CABOMETYX (Ipsen Pty Ltd)
Product name
CABOMETYX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
149 (255 working days)
Active ingredients
cabozantinib (S)-malate
Registration type
EOI
Indication
CABOMETYX is indicated for the treatment of adult patients with locally advanced/unresectable or metastatic, well-differentiated extra-pancreatic (epNET) or pancreatic (pNET) neuroendocrine tumours who have progressed on at least one prior systemic therapy other than a somatostatin analogue